Xiao-xiao Fu
Hangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Retraction notice to "C16 peptide and angiopoietin-1 alleviate the side effects of glucocorticoids in a rat multiple sclerosis model" [Life Sciences 363 (2025) 123402].
Journal: Life sciences
Published: November 28, 2025
Corrigendum: Neuroprotective effects of a novel peptide through the Rho-integrin-Tie2 and PI3K/Akt pathways in experimental autoimmune encephalomyelitis model.
Journal: Frontiers in pharmacology
Published: April 13, 2025
Neuroprotective effects of a novel peptide through the Rho-integrin-Tie2 and PI3K/Akt pathways in experimental autoimmune encephalomyelitis model.
Journal: Frontiers in pharmacology
Published: September 07, 2023
Novel nano-carriers with N-formylmethionyl-leucyl-phenylalanine-modified liposomes improve effects of C16-angiopoietin 1 in acute animal model of multiple sclerosis.
Journal: Drug delivery
Published: August 07, 2023
Co-Application of C16 and Ang-1 Improves the Effects of Levodopa in Parkinson Disease Treatment.
Journal: Journal of inflammation research
Published: April 01, 2022
Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice.
Journal: Aging
Published: April 01, 2021
Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson's disease.
Journal: NPJ Parkinson's disease
Published: December 30, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026